ALIM vs. CAPR, ME, GLSI, GOSS, TRVI, VERU, VACC, ATOS, OGI, and ACET
Should you be buying Alimera Sciences stock or one of its competitors? The main competitors of Alimera Sciences include Capricor Therapeutics (CAPR), 23andMe (ME), Greenwich LifeSciences (GLSI), Gossamer Bio (GOSS), Trevi Therapeutics (TRVI), Veru (VERU), Vaccitech (VACC), Atossa Therapeutics (ATOS), Organigram (OGI), and Adicet Bio (ACET). These companies are all part of the "pharmaceutical preparations" industry.
Alimera Sciences (NASDAQ:ALIM) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, community ranking, valuation, dividends and media sentiment.
Alimera Sciences has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Alimera Sciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Capricor Therapeutics had 6 more articles in the media than Alimera Sciences. MarketBeat recorded 8 mentions for Capricor Therapeutics and 2 mentions for Alimera Sciences. Capricor Therapeutics' average media sentiment score of 0.18 beat Alimera Sciences' score of 0.00 indicating that Capricor Therapeutics is being referred to more favorably in the news media.
99.8% of Alimera Sciences shares are owned by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are owned by institutional investors. 31.4% of Alimera Sciences shares are owned by insiders. Comparatively, 12.0% of Capricor Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Alimera Sciences has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 3.99, indicating that its share price is 299% more volatile than the S&P 500.
Alimera Sciences received 14 more outperform votes than Capricor Therapeutics when rated by MarketBeat users. However, 62.57% of users gave Capricor Therapeutics an outperform vote while only 57.72% of users gave Alimera Sciences an outperform vote.
Alimera Sciences presently has a consensus price target of $7.50, indicating a potential upside of 126.59%. Capricor Therapeutics has a consensus price target of $24.00, indicating a potential upside of 366.02%. Given Capricor Therapeutics' higher possible upside, analysts clearly believe Capricor Therapeutics is more favorable than Alimera Sciences.
Alimera Sciences has a net margin of -24.93% compared to Capricor Therapeutics' net margin of -88.52%. Alimera Sciences' return on equity of -130.90% beat Capricor Therapeutics' return on equity.
Summary
Alimera Sciences beats Capricor Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Alimera Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alimera Sciences Competitors List
Related Companies and Tools
